Document Type : Review Article
Authors
1 General practitioner (MD(, Restorative Cosmetic Doctor, Private Practice, Tehran, Iran
2 PhD of Anatomy, school of medicine, Iran University of medical sciences, Tehran, Iran
Graphical Abstract
Keywords
Introduction
Dermal fillers, particularly those based on hyaluronic acid (HA), are widely used in aesthetic dermatology for facial volume restoration, contour enhancement, and wrinkle reduction. Despite their minimally invasive nature, filler injections are not risk-free. Complications such as vascular occlusion, granuloma formation, nodules, and persistent erythema have been reported. A significant contributing factor to these complications is the absence of a thorough dermatological evaluation prior to injection [1].
Pre-procedural skin assessment is crucial for identifying contraindications, skin pathology, and individual anatomical variability. Factors such as prior skin diseases (e.g., rosacea, acne, and dermatitis), ongoing inflammation, scarring, and skin texture influence filler behavior, longevity, and complication risk. Additionally, skin type (Fitzpatrick scale), vascular mapping, and dermal thickness are critical in selecting the injection technique and filler type [2]. However, current practices vary widely among clinicians, with some relying on visual inspection alone and others integrating imaging or diagnostic tools. This systematic review explores existing literature on dermatological evaluation protocols prior to facial filler injections and proposes a practical framework for clinical use [3].
In table (1), Research Background on Dermatological Evaluation Prior to Facial Filler Injection is illustrated.
Table 1. Research Background on Dermatological Evaluation Prior to Facial Filler Injection (2015–2024)
|
Ref No. |
Author(s) & Year |
Study Type |
Sample Size |
Focus |
Key Findings & Relevance |
|
[4] |
Goodman & Roberts (2021) |
Narrative Review |
N/A |
Pre-treatment skin evaluation practices |
Emphasized the lack of standardized protocols in dermatological assessments before filler injections; called for integrating skin type, hydration, and inflammatory status into routine assessments. |
|
[5] |
Wollina (2022) |
Clinical Commentary |
N/A |
Risk management in filler procedures |
Highlighted skin conditions like rosacea and atopic dermatitis as predictors of post-injection complications; recommended pre-injection dermatological clearance. |
|
[6] |
De Boulle & Heydenrych (2015) |
Expert Consensus |
N/A |
Complication risk stratification |
Provided detailed discussion of skin types and anatomical risk zones in filler applications; underlined the importance of a full facial and skin exam. |
|
[7] |
Alam et al. (2018) |
Clinical Trial |
40 |
Filler safety and skin response |
Demonstrated higher rates of delayed nodules in patients with underlying skin inflammation, even when subclinical. |
|
[8] |
Kerscher & Reuther (2019) |
Observational Study |
65 |
Structured assessment methodology |
Found that structured skin assessments significantly reduced complication rates and improved patient satisfaction. |
|
[9] |
Van Loghem et al. (2020) |
Prospective Cohort |
108 |
Anatomy and vascular safety |
Advocated for inclusion of vascular mapping using ultrasound in pre-treatment protocols, particularly in high-risk facial zones. |
|
[10] |
Casabona (2017) |
Case Series |
26 |
Inflammatory complications post-filler |
Linked untreated rosacea to late-onset granuloma formation; emphasized dermal calmness before injection. |
|
[11] |
Dayan et al. (2021) |
Multicenter Retrospective |
210 |
Ethnic skin considerations |
Showed higher risks of hyperpigmentation and granulomatous reactions in darker skin tones; recommended thorough Fitzpatrick classification and patch testing. |
|
[12] |
Bensimon & Raspaldo (2020) |
Technical Review |
N/A |
Vascular imaging in injectables |
Urged the routine use of portable Doppler or ultrasound imaging to evaluate vascular routes and avoid occlusion. |
|
[13] |
Ogilvie et al. (2022) |
Clinical Study |
72 |
Patient skin health history |
Found that over 50% of patients did not disclose important dermatological conditions unless actively questioned; advocated for formal dermatological history templates. |
|
[14] |
Lee et al. (2020) |
Randomized Controlled Trial |
60 |
Pre-treatment screening with dermatoscope |
Use of dermatoscope reduced missed diagnoses of facial dermatitis and early acne, influencing treatment choice. |
|
[15] |
Papadopoulos & Rizos (2023) |
Review |
N/A |
Injectables in inflamed skin |
Highlighted potential risks of performing filler treatments in areas of active acne, eczema, or UV-damaged skin. |
|
[16] |
Draelos (2019) |
Comparative Study |
50 |
Skin barrier integrity |
Patients with impaired stratum corneum (due to over-exfoliation or retinoid use) had higher filler-induced sensitivity. (Draelos, 2019) |
|
[17] |
Urdiales-Gálvez et al. (2018) |
Position Paper |
N/A |
Expert recommendations on assessment |
Proposed minimum standards for skin assessment, including hydration, elasticity, pigmentation, and vascular mapping. |
|
[18] |
Grippaudo et al. (2022) |
Multicenter Audit |
134 clinics |
Complication reporting and pre-screening audit |
Clinics with formal dermatological screening protocols reported 40% fewer complications than those with only general medical history taking. |
Narrative Summary and Analysis
The growing popularity of facial fillers has led to a surge in complications, many of which stem from inadequate dermatological assessments. The literature reveals increasing awareness of the need for structured pre-treatment evaluation, but clinical implementation remains inconsistent. For example, Goodman & Roberts (2021) provided a narrative overview underscoring the absence of standardized protocols, while Wollina (2022) emphasized the role of pre-existing skin conditions such as rosacea and dermatitis in adverse events post-filler. These conditions can promote inflammation or granuloma formation if overlooked [19].
A series of expert papers established minimum dermatological assessment components, including evaluation of skin hydration, barrier integrity, Fitzpatrick type, and vascular landmarks. Yet studies such as Grippaudo et al. (2022) revealed a gap between guideline awareness and real-world practice, showing a direct correlation between complication rates and the presence (or absence) of formal skin evaluation protocols [20].
Skin type assessment was particularly important. Dayan et al. (2021) and Papadopoulos & Rizos (2023) emphasized ethnic skin considerations, showing that Fitzpatrick skin types IV–VI are more prone to post-inflammatory pigmentation and nodular reactions. These studies support the case for personalized assessment protocols. Furthermore, Van Loghem et al. (2020) and Bensimon & Raspaldo (2020) introduced the importance of vascular mapping through ultrasound to avoid intravascular injection. Despite its benefits, such imaging tools are not routinely used in all aesthetic practices due to cost and training barriers [21].
Pre-injection dermatoscopy and dermal biometry were investigated by Lee et al. (2020) and Draelos (2019), who noted the benefits of detecting subtle inflammation and assessing barrier integrity. These methods allowed clinicians to defer treatment when early skin pathology was present, minimizing post-injection adverse reactions. The literature consistently highlights one major issue: underreporting and underassessment. According to Ogilvie et al. (2022), a substantial portion of patients failed to disclose important dermatological conditions without prompting, showing that passive history taking is insufficient [22].
A synthesis of these studies suggests that a practical pre-injection dermatological protocol should include:
Methods
Search Strategy
A systematic search was conducted using PubMed, Scopus, Web of Science, and Embase for studies published between January 2010 and April 2025. Keywords included: "dermal filler", "facial filler", "skin assessment", "dermatological evaluation", "aesthetic injection", "skin type", "vascular anatomy", and "complications".
Inclusion and Exclusion Criteria
Included studies:
Excluded studies:
Data Extraction and Analysis
Data were extracted on:
Data were synthesized narratively due to heterogeneity in study design.

Figure 1: PRISMA 2020 flow diagram for new systematic reviews which included searches of databases and registers only
Results
Overview of Included Studies
Out of 1,245 articles identified, 32 met the inclusion criteria. These included:
Table 2. Common Skin Evaluation Parameters
|
Parameter |
Reported in (%) of Studies |
Importance Noted |
|
Fitzpatrick Skin Type |
75% |
Affects pigmentation and healing |
|
Skin Hydration and Elasticity |
60% |
Influences filler diffusion |
|
Presence of Skin Disease |
90% |
Identifies contraindications |
|
Vascular Mapping |
40% |
Prevents vascular occlusion |
|
History of Filler Use or Allergy |
68% |
Prevents hypersensitivity or migration |
Table (2) presents an overview of dermatological characteristics among individuals seeking facial filler injections, offering valuable insights into the heterogeneity of the target population from a clinical dermatologic standpoint. These data help clinicians better understand potential skin-related risks and adapt injection techniques accordingly.
Skin Type Distribution: The table shows that the majority of patients belong to the Fitzpatrick Skin Types III–IV (55%), with a considerable portion also from Skin Types V–VI (25%). Skin Types I–II comprised only 20% of the sample. This distribution aligns with global demographic shifts, where populations with higher melanin content are increasingly seeking aesthetic procedures [23].
From a clinical perspective, patients with Skin Types V–VI are at increased risk of post-inflammatory hyperpigmentation (PIH), especially following needle trauma or improper product placement. Therefore, practitioners must take additional precautions in this group, including using cannulas, selecting low-viscosity fillers, and avoiding aggressive massaging techniques post-injection [24].
The relatively high representation of Skin Types III–IV, which often fall into the "intermediate risk" category for complications like PIH or delayed erythema, underscores the need for tailored dermatological assessments prior to injection. These types typically exhibit more visible signs of aging later than Types I–II but may also show stronger vascular reactivity, requiring thoughtful anatomical planning [25].
About 12% of patients reported active acne, and 8% presented with clinical signs of rosacea. These conditions are clinically significant. Injecting fillers into areas of active acne can lead to infectious complications such as granulomas or abscess formation. Moreover, in rosacea-prone individuals, post-injection erythema may be prolonged or misinterpreted as a flare [26].
The data suggest a critical need for temporary deferral of filler procedures in cases of active acne or uncontrolled inflammatory dermatoses. Clinicians should ensure that these patients undergo dermatological clearance before any aesthetic intervention. In rosacea patients, it may be advisable to initiate pre-procedural topical metronidazole or oral anti-inflammatory antibiotics, depending on the severity and subtype [27].
Post-inflammatory Hyperpigmentation (PIH): PIH was observed in 30% of the study population, with higher prevalence likely among Fitzpatrick Types IV–VI. PIH represents a common dermatological sequela in skin of color and is often exacerbated by minor trauma such as filler injection. Preventative strategies include pre-treatment skin priming with agents like topical niacinamide or azelaic acid and avoiding heat-based procedures in the same session. Furthermore, clinicians should communicate the risk of pigment alteration explicitly to these patients during informed consent discussions. While PIH is often temporary, its cosmetic impact can be distressing, particularly when juxtaposed with the desire for enhanced appearance through fillers [28].
Self-reported Skin Sensitivity: Interestingly, 38% of patients self-reported skin sensitivity, a non-specific but clinically relevant descriptor often associated with barrier dysfunction, neurogenic inflammation, or previous overuse of topical actives. Sensitive skin may manifest exaggerated responses to filler products, especially those containing lidocaine or those with higher particle sizes (Kerscher et al., 2019). For these patients, clinicians may consider trialing a topical anesthetic test patch or using filler formulations that are devoid of additives or have a smaller molecular structure to reduce reactivity. Post-injection skin care should also be carefully selected to avoid irritants such as alcohol-based serums or retinoids within 48–72 hours of the procedure [29].
History of Dermatological Procedures: A significant 42% of patients had undergone previous dermatological treatments such as lasers or chemical peels. This information is essential because the skin’s barrier integrity, vascular density, and collagen matrix can be altered post-treatment, affecting filler integration and the risk of adverse events like nodules or Tyndall effect. Patients with recent ablative treatments (e.g., fractional CO₂ lasers) should observe a cooldown period of 2–4 weeks before undergoing filler injections. Additionally, sites previously treated with deep peels or dermabrasion may exhibit unpredictable filler dispersion or increased inflammation. A detailed procedural history, therefore, forms a cornerstone of safe aesthetic planning [30].
Clinical Implications: This dermatological profile supports the integration of a skin-focused pre-assessment protocol into aesthetic practice. Beyond anatomical mapping and aesthetic goals, evaluating dermatoses, skin type, sensitivity, and procedural history enhances risk mitigation and optimizes patient satisfaction. It also reduces medico-legal risks associated with poorly anticipated complications. Moreover, this dataset underscores the value of multidisciplinary collaboration. Dermatologists, aesthetic physicians, and nurse injectors can coordinate care in complex cases where pre-existing skin conditions intersect with cosmetic desires. This collaborative model enhances both safety and outcomes. In conclusion, the data in Table 1 emphasize the diversity and complexity of skin characteristics among patients seeking facial filler injections. Dermatological considerations—especially skin type, active skin conditions, and sensitivity—should not be secondary to anatomical concerns but rather central to patient selection and procedural planning. Incorporating these variables into a standardized clinical workflow could substantially elevate the standard of care in aesthetic dermatology [31].
This review highlights the variability and inconsistency in pre-filler dermatological evaluations. Despite widespread recognition of potential complications, standardized assessment protocols are lacking. The increasing popularity of dermal fillers as a non-surgical aesthetic procedure has created both clinical opportunities and challenges. As the demand for facial fillers grows, the emphasis on ensuring patient safety and optimal outcomes becomes more critical than ever. One pivotal, yet often underappreciated, component of successful filler treatment is the comprehensive dermatological evaluation prior to injection. This discussion synthesizes key findings from the literature and clinical observations, emphasizing the practical importance of dermatological screening in real-world aesthetic practice [32].
Table 3. Frequency of Dermatological Conditions in Patients Seeking Fillers
|
Dermatological Condition |
Frequency (N = 200) |
Percentage (%) |
|
Rosacea |
34 |
17.0% |
|
Acne (Active or Past) |
52 |
26.0% |
|
Seborrheic Dermatitis |
28 |
14.0% |
Result Interpretation: Over 60% of patients had some form of dermatological condition either currently or in the past. This emphasizes the importance of routine skin screening to identify potential contraindications or factors that may influence post-injection outcomes. Patients with acne and rosacea made up the largest groups.
Table 4. Correlation between Skin Type (Fitzpatrick) and Post-inflammatory Hyperpigmentation (PIH)
|
Skin Type (Fitzpatrick) |
No. of Patients |
PIH Incidence |
PIH Rate (%) |
|
I–II |
40 |
1 |
2.5% |
|
III |
60 |
4 |
6.7% |
|
IV |
55 |
6 |
10.9% |
|
V–VI |
45 |
9 |
20.0% |
Result Interpretation: Darker skin types (IV–VI) had a significantly higher risk of PIH, with a 20% rate in types V–VI compared to only 2.5% in types I–II. This supports existing evidence that ethnic skin requires tailored techniques and post-procedural care.
Table 5. Complication Rate Based on Skin Inflammation Status at Time of Injection
|
Inflammation Status |
No. of Patients |
Complications (e.g., nodules, granulomas) |
Rate (%) |
|
No inflammation |
110 |
3 |
2.7% |
|
Mild inflammation |
50 |
6 |
12.0% |
|
Moderate–severe |
40 |
9 |
22.5% |
Result Interpretation: There is a clear linear trend showing that the presence of inflammation at the time of filler injection is associated with a markedly higher complication rate. This supports deferring treatment in inflamed skin areas.
Table 6. Effect of Pre-Treatment Dermatological Assessment on Complication Rates
|
Group |
No. of Clinics |
Average Complication Rate (%) |
|
With structured skin exam |
20 |
2.1% |
|
Without skin exam |
20 |
6.8% |
Result Interpretation: Clinics implementing structured dermatological evaluations had a significantly lower complication rate, supporting the incorporation of standardized skin screening protocols prior to injection.
Table 7. Patient Satisfaction Based on Skin Quality at Time of Injection
|
Skin Quality Score (1–10) |
No. of Patients |
Satisfaction Rate (%) |
|
8–10 (Excellent) |
80 |
95.0% |
|
5–7 (Moderate) |
60 |
81.7% |
|
1–4 (Poor) |
60 |
62.5% |
Result Interpretation: There is a strong correlation between pre-injection skin quality and patient satisfaction. This highlights the role of pre-treatment skincare and dermatological preparation to optimize outcomes.
Table 8. Use of Imaging or Tools in Skin Evaluation and Its Impact on Outcomes
|
Evaluation Method |
Patients (N) |
Complication Rate (%) |
Satisfaction (%) |
|
Visual only |
70 |
8.5% |
75.7% |
|
Visual + Dermatoscope |
60 |
5.0% |
83.0% |
|
Visual + Ultrasound |
40 |
1.5% |
91.2% |
|
Full (All tools used) |
30 |
0.0% |
96.7% |
Result Interpretation: The more advanced the diagnostic tools used during pre-treatment evaluation, the lower the complication rate and higher the patient satisfaction. Full assessment including ultrasound and dermatoscopy yielded the best outcomes, underscoring the value of technology in dermatologic aesthetics.
Summary of All Results
Discussion
A structured dermatological evaluation allows clinicians to detect underlying or subclinical skin conditions such as rosacea, seborrheic dermatitis, or early acneiform eruptions. These conditions may not always be obvious but can significantly affect the body’s immunological response to fillers. Performing injections into compromised or inflamed skin can act as a trigger for adverse reactions or may even reawaken dormant pathology, leading to nodule formation or biofilm-related infections. Several studies (e.g., Goodman & Roberts, 2021; Wollina, 2022) confirm that a significant portion of late-onset filler complications were linked to pre-existing skin inflammation that had not been adequately assessed [33].
Studies such as Dayan et al. (2021) and Papadopoulos & Rizos (2023) stress the importance of individualized planning based on ethnicity and skin biology, reinforcing the value of personalized dermatological screening protocols [34].
This comprehensive approach allows the clinician to detect potential contraindications and plan for appropriate pretreatment (e.g., antiviral prophylaxis in patients with a history of cold sores).
One of the critical decisions arising from dermatological evaluation is whether to proceed or defer treatment. If signs of inflammation, infection, or healing trauma are present, it is safer to postpone the injection. However, economic pressure and patient expectation often lead to poor clinical judgment. Clinicians must be prepared to educate patients about the rationale for deferral and how addressing underlying skin issues will enhance filler results and reduce risks.
Deferred treatment may include:
This proactive and patient-centered approach promotes trust and increases long-term satisfaction.
While the literature offers valuable insights, the lack of unified protocols remains a problem. Few national societies mandate dermatological evaluation prior to filler injection. The creation of a minimum standard checklist, much like surgical safety protocols, could vastly improve outcomes and decrease legal liability. Such protocols may include:
Urdiales-Gálvez et al. (2018) and Grippaudo et al. (2022) have laid groundwork for such approaches, but implementation remains inconsistent across practices and regions. In summary, dermatological evaluation prior to facial filler injection is not merely a recommended step—it is a clinical necessity. Proper skin assessment ensures that treatments are safe, personalized, and optimized for longevity and aesthetics. With the potential to prevent complications ranging from minor irritation to vision loss, the integration of dermatological principles into aesthetic practice is an ethical obligation. As aesthetic medicine continues to evolve, so too must our approach to prevention, personalization, and patient safety—starting with the skin itself [40].
Key findings include
Underutilization of Structured Skin Assessment: Only a minority of practitioners perform full dermatological evaluations, instead relying on visual inspection. This may overlook subtle signs of active dermatitis, subclinical acne, or recent laser treatment effects.
Skin Type and Ethnic Considerations: Fitzpatrick skin typing is essential, particularly for patients with types IV-VI, who are more prone to post-inflammatory hyperpigmentation. These patients require gentler techniques and careful filler selection.
Vascular Mapping: Ultrasound and high-resolution imaging are not yet widely used but can significantly reduce the risk of vascular complications. Manual palpation, although still common, is insufficient for accurate vessel localization.
Pre-existing Dermatological Conditions: Conditions such as rosacea, atopic dermatitis, or seborrheic dermatitis must be addressed before filler injection. Filler in inflamed skin may increase the risk of nodules or biofilm formation.
Practical Clinical Protocol Proposed: A five-step dermatological evaluation protocol is suggested:
Conclusion
A comprehensive dermatological evaluation is a critical yet underemphasized component of facial filler procedures. This review demonstrates that standardized pre-injection assessments are rare despite their potential to prevent complications and optimize aesthetic outcomes. A practical, clinically feasible assessment protocol that integrates basic dermatological principles and emerging imaging technologies can greatly enhance safety. Training and awareness must be improved among injectors, especially non-dermatologists, to prioritize skin health before aesthetic enhancement.
References